Professional
Added to YB: 2024-10-31
Pitch date: 2024-09-30
HALO [bullish]
Halozyme Therapeutics, Inc.
+9.2%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
Market Cap
$8.3B
Pitch Price
$56.97
Price Target
N/A
Dividend
N/A
EV/EBITDA
11.07
P/E
14.83
EV/Sales
7.32
Sector
Biotechnology
Category
growth
Show full summary:
Artisan Global Equity Fund Portfolio Holding: Halozyme Therapeutics, Inc.
HALO: Roche's OCREVUS ZUNOVO & TECENTRIQ Hybreza approved in US using ENHANZE tech for subcutaneous delivery, cutting treatment time. Mid-single-digit royalties. EU approval earlier. Long-term cash generation potential supports buybacks. Share price up on approvals.
Read full article (1 min)